Glenmark Pharma Share Price Target 2026, 2027, 2028, 2029, 2030

Glenmark Pharma share price today

Glenmark Pharmaceuticals (NSE: GLENMARK) spent a decade as the cautionary tale — innovation dreams funded by debt — and has emerged as something the market half-believes: a deleveraged (D/E 0.06) company whose innovation arm finally produced a global validation. The AbbVie partnership for ISB-2001, its blood-cancer candidate from the Ichnos platform, brought a large upfront and up to billions in milestones — the kind of external endorsement Indian pharma innovation almost never receives.

The result: 39.8% ROCE, 30.5% ROE, and a stock still at 20.6× with a PEG of 0.8. The valuation looks attractive against the progress, but the caveats still matter.

The re-rating that’s only half done

Three businesses live here. The India branded franchise (respiratory, dermatology — Telma is a flagship) compounds steadily. The global generics/branded mix has been pruned toward profitability rather than scale. And Ichnos-Glenmark Innovation — the piece the market wrote down to zero for years — now carries the AbbVie deal’s economics and a pipeline behind it. Profit grew at 25.7% annually over five years through the clean-up; margins (27% OPM) now resemble quality pharma, not a leveraged experiment.

Watch-items: milestone-dependency (deal income is lumpy and binary), FDA compliance history (Glenmark’s record has scars), sustaining India-business growth, and whether management resists re-leveraging for the pipeline.

The numbers

Financial snapshot — 5 August 2026

Metric	Value
Market cap	₹64,271 Cr
P/E (TTM)	20.6
EV/EBITDA	12.0
Operating margin	27.0%
ROE / ROCE	30.5% / 39.8%
Debt to equity	0.06
Sales CAGR (5y)	9.2%
Profit CAGR (5y)	25.7%
Promoter holding	46.7% (zero pledged)
EPS (TTM)	₹108.1

Glenmark Pharma share price target 2026 to 2030

EPS base ₹108.1 (TTM — includes deal economics; scenarios haircut accordingly). Bear: milestones stall and base business carries alone — 5% growth, multiple at 15×. Base: India compounds and milestones trickle — 11% growth at 19×. Bull: ISB-2001 advances and innovation gets priced — 15% growth at 25×.

From ₹2,225, the base case is ≈ +56% over four and a half years; the bear is roughly −7%. The spread is relatively tight because the starting multiple is modest: at 20×, the innovation story is not the only support for the valuation, but it can add upside if it works.

Reasons to own Glenmark (at the right price)

1. PEG 0.8 with 40% ROCE — quality metrics at a value multiple.
2. The balance-sheet repair is done: D/E 0.06 removes the historic bear case.
3. AbbVie’s ISB-2001 deal is external validation of the innovation platform — with milestone economics attached.
4. The India branded business is a steady compounder beneath the story.
5. The valuation still looks modest beside the operational progress.

The risks: milestone income is lumpy and can vanish on trial data, US FDA history warrants humility, and base-business growth (9.2% five-year sales CAGR) is modest without the innovation kicker.

What to weigh at the current price

At 20.6× earnings, Glenmark’s cleaner balance sheet and AbbVie validation create genuine rerating potential, but milestone income is lumpy and FDA execution still matters. The case rests on steady branded-pharma cash flows without a return to debt-funded ambition.

FAQ

What is the Glenmark share price target for 2030? The table above presents bear, base and bull paths through 2030. Each depends on the stated EPS-growth and valuation assumptions; none is a guaranteed outcome.

What is ISB-2001? A trispecific antibody for multiple myeloma from Glenmark’s Ichnos innovation platform — partnered with AbbVie in a deal carrying a large upfront and milestone ladder, the strongest external validation an Indian-discovered molecule has received.

Is Glenmark still highly indebted? No — the deleveraging is complete (debt-to-equity 0.06). That transformation is much of why the stock re-rated.

When are Glenmark’s next results? Check the results calendar and confirm the announced date in the exchange filing.

---

This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.